The records of fifteen patients referred for neurological assessment and found to have lupus anticoagulant or elevated anticardiolipin antibodies were reviewed. The mean age for females in the group was 29.4 years and for males was 35. A diagnosis of migraine, either as an acute or chronic problem, was made in 10 (66%) of these patients. Seven of the 15 patients had ischemic stroke and two patients had other thrombotic complications associated with lupus anticoagulant. Three of the nine female patients with migraine had histories of spontaneous abortions. All migraine patients experienced transient or more prolonged neurological deficits with their headaches. An association between lupus anticoagulant and migraine can only be suggested. Data on the incidence of migraine in patients with lupus anticoagulant in the general medical population does not exist. Furthermore the prevalence of lupus anticoagulant in migraine sufferers is unknown. Therefore further studies are required to investigate this possible association. RESUME: Anticoagulant lupique, anticorps antiphospholipide et migraine Les dossiers de quinze patients referes pour evaluation neurologique, chez qui on avait mis en evidence un anticoagulant lupique ou un taux eleve d'anticorps anticardiolipine, ont ete revises. Dans ce groupe de patients, l'age moyen des femmes etait de 29.4 ans et celui des hommes de 35 ans. Un diagnostic de migraine a ete pose chez 10 (66%) de ces patients, tant chez ceux dont le probleme etait aigu que chez ceux chez qui il etait chronique. Sept des quinze patients avaient fait un accident cerebro-vasculaire d'origine ischemique et deux patients presentaient d'autres complications thrombotiques associees a I'anticoagulant lupique. Trois des neuf patientes migraineuses avaient une histoire de fausses couches. Tous les patients migraineux avaient presente des deficits neurologiques transitoires ou prolonges accompagnant leurs cephalees. Une association entre I'anticoagulant lupique et la migraine ne peut qu'etre suggeree. II n'existe pas de donnees sur l'incidence de la migraine chez les patients qui ont un anticoagulant lupique dans la population generale venant a l'attention medicale. De plus, la prevalence de I'anticoagulant lupique chez les patients souffrant de migraines est inconnue. Par consequent, il est necessaire de proceder a des etudes supplementaires pour investiguer la possibilite qu'une telle association existe.
Lupus anticoagulant (LAC) is an IgG or less frequently an IgM antibody that belongs to a group of antibodies directed against phospholipid. LAC was first identified in 1952 in two patients with systemic lupus erythematosus (SLE) who were reported to have a bleeding tendency. 1 Espinoza and Hartmann 2 in a recent review reported a prevalence of LAC of approximately 10% in SLE but a wide range (6% to 71%) has been reported elsewhere. 3 LAC has also been identified in patients who do not have other features of SLE. Schleider et al 4 and Gastineau et al 5 reported on 58 and 219 identified cases of LAC respectively and both groups found that approximately half of the patients studied did not have SLE.
Although the LAC has an in vitro anticoagulant effect (by neutralizing the procoagulant phospholipids in the assay system 3 ) most patients with these antibodies have a tendency to develop thrombotic complications. '• 3 - 6 Bleeding is an unusual complication and when it occurs there is usually some other defect in the clotting mechanism.
1 ' 35 ' 7 The incidence of thrombosis in SLE patients with LAC has been reported to range from 23% to 58%. 7 ' 8 ' 9 The incidence of thrombosis in SLE patients without LAC is approximately 15%. 9 ' 10 Patients with LAC who do not have SLE have a similar risk for thrombotic complications as patients with both LAC and SLE. 5 The reason for the thrombotic tendency in patients with LAC has not been determined. There is a strong, but not absolute correlation, between LAC and elevated antibodies to the phospholipid cardiolipin." Elevated anticardiolipin antibody (ACA) levels have been shown to be associated with thrombotic complications.
11 ' 12 Among the theories proposed for the thrombotic pathogenesis of LAC and antiphospholipid antibodies is the inhibition of PGI2 production by interaction of the antibodies with phospholipid within endothelial cell membranes.
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PGI2 is a vasodilator and an inhibitor of platelet aggregation produced by endothelial cells. It has also been suggested that platelets may be predisposed to aggregation secondary to membrane bound antiphospholipid antibody.
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Central nervous system complications are recognized in LAC patients. These are principally due to cerebrovascular thrombotic events which have been reported to occur in 3% to 18% of patients with LAC. 5 22 reported two cases of migraine with lupus anticoagulant. These patients did not have SLE at the time of assessment. In a review of the literature these authors identified six other cases of migraine occurring in patients with lupus anticoagulant in addition to the cases noted above. They suggest that alteration of platelet membrane phospholipids due to LAC or possibly interaction of LAC with neuronal phospholipid may be responsible for migraine in these patients.
We have recently recognized a group of young patients who presented with histories of migraine and/or neurological deficits (transient or prolonged) who were found to have either LAC or ACA or both. In only a few of these patients were other major risk factors for stroke identified and only one patient has gone on to develop features consistent with SLE. It is the purpose of this paper to present our initial experience with LAC and to suggest a possible association with migraine.
METHODS
We reviewed the records of 15 patients seen by the neurology service at Kingston General Hospital who were found to have lupus anticoagulant and/or anticardiolipin antibodies. Twelve of these patients presented since July 1986. In the other three patients LAC had been recognized several years earlier.
The LAC was detected by two methods. Initial screening was done with an activated partial thromboplastin time test (APTT reagent -Actin FS, American Dade). Presence of the LAC was confirmed using Exner's Kaolin clotting time method. 23 Cardiolipin antibodies were measured by a modification of the ELISA method described by Koike et al. 24 Results were expressed in arbitrary units (AU) where one AU is 1 standard deviation above the mean for the normal control population (50 normal subjects). Values for the IgM and IgG ACA in excess of 3 AU were regarded as positive.
Migraine is a clinical diagnosis and the features of this disorder have been well documented.25,26,27,28 i n t m s study patients were diagnosed as having classical migraine, common migraine, complicated migraine or basilar artery migraine. Classical migraine referred to a typical migrainous headache following a brief transient neurological deficit while common migraine was not associated with a neurological deficit. In complicated migraine the neurological deficit persisted during and after the headache. The features of basilar artery migraine have been described by Bickerstaff. 28 Neurological symptoms and signs were considered to be transient if resolution occurred within 24 hours.
RESULTS
The clinical and laboratory data of all 15 patients are summarized in Tables 1 and 2 . Twelve of the patients (80%) were female. The average age at the time of diagnosis of LAC was 29.4 years (19 to 49) for females and 35 years for males. A history of migraine was identified in 10 of the 15 patients in this study.
Six patients were initially referred to the neurology service for assessment of headache and migraine was diagnosed in five (cases 1, 6, 8, 9, 10) . Two of these patients (cases 8,9), who had histories of recurrent thrombotic complications and spontaneous abortions, had already been identified as having LAC but their migraine problem had not been assessed. The remaining patient (case 15) had non-migrainous headache.
Three patients (cases 2,3,4,) developed neurological deficits acutely and a diagnosis of complicated migraine was made after initial investigations failed to identify other possible etiologies for their symptoms and signs. One of these patients (case 3) was recognized to have a long history of common migraine and reported increased severity of headaches in the 6 months prior to her presentation.
One patient (case 5) presented with an acute cerebral ischemic event and was found to have had recent onset of classical migraine. Two other patients (cases 11,13) presented with acute focal neurological deficits and CT head scan evidence of infarcts but did not have a migraine history. Two patients (cases 12,14) presented with fluctuating sensory symptoms and no history of migraine. The final patient (case 7) presented with a four week history of gradually developing hemichoreoathetosis and a 15 month history of migraine. Within the following month she developed sufficient features to establish a diagnosis of SLE.
Seven patients were identified as having ischemic stroke. Four of these cases (1, 2, 3, 5) were from the migraine group. Major risk factors for stroke (apart from antiphospholipid antibodies) were identified in two patients; one was hypertensive (case 13), and the other had diffuse narrowing of the left internal carotid artery on angiography (case 5). No other vascular abnormalities were detected in the stroke group of patients.
The birth control pill (BCP) was used by seven patients, six of them being in the migraine group. Two of the patients with stroke were using the BCP (cases 2,5).
Three female patients (cases 1,6,8) had one or more spontaneous abortions which are a recognized complication of LAC. 3 Two patients (cases 8,9) had experienced considerable morbidity secondary to the thrombotic tendency caused by LAC.
LAC was identified in 12 patients. The three patients negative for LAC (cases 10, 11, 14) showed evidence of elevated ACA levels. Elevated ACA levels were present in a total of 11 patients. Other serology included the VDRL which was positive in only one case (15) . Positive ANA titres were seen in a total of five patients. Three of the migraine group had positive ANA titres including the one patient that has developed SLE (case 7). DISCUSSION A total of 10 LAC cases with migraine have been reported in the literature. 22 In our group of 15 patients with LAC migraine was diagnosed in 10. In 7 of these patients migraine was either an acute presenting problem (cases 2,4), had developed over the preceding 15 months (cases 5,6,7) or was a long standing problem that had become more severe in the preceding year (cases 1,3). In the remaining three patients (cases 8,9,10) there was a long unchanging history of migraine. None of the patients in the migraine group suffered from common migraine alone. All of the migraine sufferers had experienced either transient or more prolonged neurological symptoms and signs. It is possible that several of our cases (2,3,4) who were diagnosed as complicated migraine may have simply suffered from TIA or stroke with an accompanying headache. However the gradual progression of neurological deficits observed in case 2 is much more typical of classical migraine than stroke. Case 3 had clearly suffered from worsening headaches typical of common migraine prior to her presentation. Only case 4 had no previous headache history.
Our group of migraine patients represents a selected population. Four of the 10 patients had suffered an ischemic stroke at a relatively young age. Vascular abnormalities were only identified in one of these patients (case 5). Three of our nine female migraine patients had one or more spontaneous abortions. Two patients had previously suffered deep venous thromboses and one patient developed SLE. However, it must be noted that apart from a tendency for thrombotic complications eight of our ten migraine patients with LAC were otherwise well. It is of interest to also note that three of our patients without other underlying disease reported feeling generally fatigued and that this eased considerably when therapy with ASA was instituted.
The birth control pill was used by 7 of our 12 female patients but without a control population we are unable to comment on any possible significance of this finding.
There was not an absolute correlation between LAC and elevated ACA levels in our patients. This has been recently reported 29 and suggests that we may be looking at a range of antibodies with overlapping activity rather than a single antibody against a specific epitope. In our three ACA positive -LAC negative patients no thrombotic complications or stroke were documented. Otherwise no differences between our LAC negative and LAC positive patients was recognized.
Only two patients had prolonged partial thromboplastin times (PTT). Twelve patients however were positive for LAC using the kaolin clotting time (KCT). This can be explained by the relative insensitivity of the PTT reagent used (Dade Actin FS) to the effects of LAC. Therefore if LAC is suspected clinically a more sensitive test such as the KCT should be performed.
At this time the prevalence of migraine in the population of patients with antiphospholipid antibodies is not known. We also do not know the prevalence of these antibodies in the normal population or the population that attends neurology clinics. Therefore, even in our cases where there had been a recent change in migraine status, we do not know if the association with lupus anticoagulant was merely coincidental or if migraine patients with LAC represent some subgroup of the migraine population with a specific, as yet unknown, pathophysiology. However this data raises the question of a possible association between LAC and migraine and further investigation into this problem is warranted.
